At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

Who doesn’t like a good discount? If the 167 million people who vistied physical and online stores last year are any ...

AbbVie, Inc. (ABBV) is currently at $165.64, down $4.00 or 2.36% --Would be lowest close since July 3, 2024, when it closed at $163.84 --Currently down eight consecutive days; down 17.87% over this ...

Dillard's Capital Trust I 7.5% Pfd.-0.04% ...

AVIC Shenyang Aircraft Co. Ltd. A-3.22% ¥143.5B ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...